0000899243-19-009670.txt : 20190402 0000899243-19-009670.hdr.sgml : 20190402 20190402200200 ACCESSION NUMBER: 0000899243-19-009670 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190313 FILED AS OF DATE: 20190402 DATE AS OF CHANGE: 20190402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLECH ISAAC CENTRAL INDEX KEY: 0000905536 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 19727174 MAIL ADDRESS: STREET 1: C/O INSPIREMD, INC. STREET 2: 321 COLUMBUS AVENUE CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2019-03-13 2019-03-14 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0000905536 BLECH ISAAC C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIDGE MA 02139 1 0 0 0 Stock Option (right to buy) 6.84 2019-03-13 4 A 0 70796 A 2025-12-14 Common Stock 70796 70796 D Stock Option (right to buy) 18.66 2019-03-13 4 A 0 6854 0.00 A 2029-03-13 Common Stock 6854 6854 D Fully vested. Reflects the Reporting Person's stock option to acquire 744,967 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). 33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger. All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4/A reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger. /s/ Adam S. Mostafa, attorney-in-fact 2019-04-02